GoCART Coalition
Study type:
Study number:
Type of treatment:
CAR T
Diseases:
Non-Hodgkin’s Lymphoma (NHL)
Short title:
BRIDGING
Primary objective:
1. To evaluate the impact of bridging therapy by comparing the disease status at apheresis to the disease status at lymphodepletion (considered as disease status at CART).
2. To evaluate the impact of bridging therapy (and a possible change of disease status between apheresis and lymphodepletion) on outcomes post CART: PFS, OS, RI, NRM, partial/complete remission, subsequent CART/allogeneic HSCT, CRS and ICANS.
2. To evaluate the impact of bridging therapy (and a possible change of disease status between apheresis and lymphodepletion) on outcomes post CART: PFS, OS, RI, NRM, partial/complete remission, subsequent CART/allogeneic HSCT, CRS and ICANS.
Key inclusion criteria:
- Patients aged 18 years or above at time of CART infusion.
- Diagnosis of DLBCL, HGBCL, PMBCL, T-cell/histiocyte rich LBCL
- First chronological CART infusion before July 2023
- Diagnosis of DLBCL, HGBCL, PMBCL, T-cell/histiocyte rich LBCL
- First chronological CART infusion before July 2023
Country:
All EBMT member countries
Principal investigator:
Philipp Berning
EBMT Study coordinator:
Eva MICHEL
Study coordinator email:
eva.michel@ebmt.org
EBMT Study Unit:
Paris Study Unit
Reason for processing personal data:
Research and Development of new and improved transplant, cell therapy and immunosuppression procedures.
Categories of personal data collected:
DOB/YOB, gender
Medical data already reported to the EBMT Registry
Study Specific Questionnaire (MED-C)
Recipients who may access the data:
Paris Study Unit
3rd-party processors of Personal Data on behalf of EBMT/Service provider:
No
Privacy notices
Article 6 lawful basis for processing personal data:
Article 6.1 (a) - Consent (Collection)
Article 9 basis for processing special category data:
Article 9(2) (a) - Consent (Collection)
Data Protection Impact Assessments
Rights available to individuals:
Access
Data portability
Rectification
Objection
Deletion
Is a Data Protection Impact Assessment required?:
Not applicable to surveys
Retention Schedule (if possible):
at least 5 years after the final report or first publication of study results